BR112013032188A2 - composition, product and method for treating patients with chronic hepatitis C - Google Patents

composition, product and method for treating patients with chronic hepatitis C

Info

Publication number
BR112013032188A2
BR112013032188A2 BR112013032188A BR112013032188A BR112013032188A2 BR 112013032188 A2 BR112013032188 A2 BR 112013032188A2 BR 112013032188 A BR112013032188 A BR 112013032188A BR 112013032188 A BR112013032188 A BR 112013032188A BR 112013032188 A2 BR112013032188 A2 BR 112013032188A2
Authority
BR
Brazil
Prior art keywords
composition
product
chronic hepatitis
treating patients
patients
Prior art date
Application number
BR112013032188A
Other languages
Portuguese (pt)
Inventor
Francisco Javier Cámara Martín
Iranzu González De La Tajada
Juan Ruiz Echeverría
Pablo Miguel Ortiz Betés
Original Assignee
Digna Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digna Biotech Sl filed Critical Digna Biotech Sl
Publication of BR112013032188A2 publication Critical patent/BR112013032188A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

abstract not avaibleabstract not avaible

BR112013032188A 2011-06-23 2012-06-22 composition, product and method for treating patients with chronic hepatitis C BR112013032188A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382214 2011-06-23
PCT/EP2012/062128 WO2012175700A1 (en) 2011-06-23 2012-06-22 Treatment of chronic hepatitis c with ifn-a5 combined with ifn-a2b in a cohort of patients

Publications (1)

Publication Number Publication Date
BR112013032188A2 true BR112013032188A2 (en) 2016-12-20

Family

ID=46354339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032188A BR112013032188A2 (en) 2011-06-23 2012-06-22 composition, product and method for treating patients with chronic hepatitis C

Country Status (4)

Country Link
CN (1) CN103732242A (en)
BR (1) BR112013032188A2 (en)
RU (1) RU2014102102A (en)
WO (1) WO2012175700A1 (en)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
JP4327910B2 (en) 1997-03-14 2009-09-09 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of IMPDH enzyme
JP4452401B2 (en) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Hepatitis C virus inhibitory peptide analog
ES2138565B1 (en) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra USE OF INTERFERON ALPHA 5 IN THE TREATMENT OF VIRAL ES HEPATOPATHIES.
JP4184610B2 (en) 1999-03-19 2008-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of IMPDH enzyme
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
ES2336009T3 (en) 2004-01-30 2010-04-07 Medivir Ab INHIBITORS OF THE NS-3 SERINA PROTEASA HCV.
CN102459647B (en) * 2009-05-21 2015-05-06 默沙东公司 Genetic markers associated with interferon-alpha response
EP2459211A1 (en) * 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
CN101750474A (en) * 2009-09-16 2010-06-23 陈利民 Method of predicting therapeutic effect of interferon treatment on hepatitis C

Also Published As

Publication number Publication date
RU2014102102A (en) 2015-07-27
WO2012175700A1 (en) 2012-12-27
CN103732242A (en) 2014-04-16

Similar Documents

Publication Publication Date Title
BR112013032229A2 (en) hydrothermal hydrothermal biomass treatment method, and, composition
BR112013025006A2 (en) compositions and methods for inhibiting tmprss6 gene expression
BR112014007649A2 (en) structuring material and method for the treatment of an underground formation
BR112014007619A2 (en) cosmetic composition, and method for enhancing at least one property
PL2672966T3 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201490559A1 (en) COMPOSITION FOR THE TREATMENT OF Fistula
RS61827B1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112013027716A2 (en) quick drawers with rollers and ramp
BR112013024211A2 (en) solid tumor treatment
BR112014012498A2 (en) anti-cd20 antibody and method for cancer treatment
BR112014009889A2 (en) disubstituted compounds, compounds and pharmaceutical composition
BR112013024363A2 (en) method, and apparatus
EA201491286A1 (en) METHOD OF TREATING BONE LOSS OF ALVEOLAR PROCESS BY MEANS OF ANTIBODIES TO SCLEROSTIN
BR112014031512A2 (en) cosmetic composition and method for cosmetic treatment.
BR112013029484A2 (en) method for treating advanced solid tumors
BR112013022306A2 (en) Method and composition
BR112014022694A2 (en) new methods and compositions for treating disease
UY34070A (en) METHOD AND COMPOSITION FOR SEED TREATMENT.
EA201590503A1 (en) ALPHA-1-Microglobulin for use in the treatment of diseases associated with mitochondria
BR112015011131A2 (en) method and machine for making sanitary absorbent articles
BR112014012759A8 (en) compound, composition and method for treatment
BR112013028890A2 (en) compositions and methods for cancer treatment
BR112013019224A2 (en) composition, and method
BR112013023253A2 (en) method for making an absorbent article
UY34340A (en) PLANTS THAT HAVE TRACKS RELATED TO STRESS AND METHODS TO PRODUCE THE SAME.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)